glp-1 pancreatitis class action in michigan Risk of pancreatic cancer associated with receptor agonist therapy Glucagon-like Peptide 1 Receptor Signaling
Description
Treatment starts at 2.5 mg and increases by 2.5 mg every four weeks until reaching the maximum tolerated dose
New England Journal of Medicine, 384 (11), 9891002
Hoover R
Patients should be aware of the signs to watch for, such as nausea, vomiting, and abdominal pain, which may necessitate a reassessment of their treatment plan
PPO insurances require Prior Authorization
These effects result in very significant weight loss (15-20% of initial body weight), i.e., of the same order of magnitude as that obtained by bariatric surgery
